Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
Publication
, Journal Article
Haas, DW; Bartlett, JA; Andersen, JW; Sanne, I; Wilkinson, GR; Hinkle, J; Rousseau, F; Ingram, CD; Shaw, A; Lederman, MM; Kim, RB ...
Published in: Clin Infect Dis
September 15, 2006
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).
Duke Scholars
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
September 15, 2006
Volume
43
Issue
6
Start / End Page
783 / 786
Location
United States
Related Subject Headings
- South Africa
- Reverse Transcriptase Inhibitors
- Randomized Controlled Trials as Topic
- Polymorphism, Genetic
- Oxidoreductases, N-Demethylating
- Nevirapine
- Microbiology
- Male
- Liver Diseases
- Liver
Citation
APA
Chicago
ICMJE
MLA
NLM
Haas, D. W., Bartlett, J. A., Andersen, J. W., Sanne, I., Wilkinson, G. R., Hinkle, J., … Adult AIDS Clinical Trials Group, . (2006). Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis, 43(6), 783–786. https://doi.org/10.1086/507097
Haas, David W., John A. Bartlett, Janet W. Andersen, Ian Sanne, Grant R. Wilkinson, John Hinkle, Franck Rousseau, et al. “Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.” Clin Infect Dis 43, no. 6 (September 15, 2006): 783–86. https://doi.org/10.1086/507097.
Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15;43(6):783–6.
Haas, David W., et al. “Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.” Clin Infect Dis, vol. 43, no. 6, Sept. 2006, pp. 783–86. Pubmed, doi:10.1086/507097.
Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB, Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15;43(6):783–786.
Published In
Clin Infect Dis
DOI
EISSN
1537-6591
Publication Date
September 15, 2006
Volume
43
Issue
6
Start / End Page
783 / 786
Location
United States
Related Subject Headings
- South Africa
- Reverse Transcriptase Inhibitors
- Randomized Controlled Trials as Topic
- Polymorphism, Genetic
- Oxidoreductases, N-Demethylating
- Nevirapine
- Microbiology
- Male
- Liver Diseases
- Liver